Pediatric Pulmonary Hypertension Registry: Real-world Outcomes and Epidemiology
Insights Into Epidemiology, Management, and Outcomes of Pediatric Pulmonary Hypertension: The INSPIRE-PH Multicenter Real-World Registry
This registry collects long-term clinical data from children and adolescents with pulmonary hypertension to see how the disease progresses and how real-world treatments work.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 450 (estimated) |
| Ages | N/A to 18 Years |
| Sex | All |
| Sponsor | Guangdong Provincial People's Hospital Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT07495774 on ClinicalTrials.gov |
What this trial studies
INSPIRE-PH is a multicenter, observational real-world registry that systematically collects longitudinal clinical and outcome data on children and adolescents diagnosed with pulmonary hypertension. Enrolled patients receive standard care from their treating physicians and no study-mandated interventions are imposed. The registry captures diagnostic, hemodynamic, treatment, and follow-up information to characterize disease course, treatment patterns, and prognosis over time. The cohort began prospectively in 2006 and cases have been reclassified according to contemporary World Symposium on Pulmonary Hypertension criteria to enable longitudinal comparisons.
Who should consider this trial
Good fit: Children and adolescents diagnosed with pulmonary hypertension before age 18 who can provide informed consent/assent and are able to attend longitudinal follow-up at participating centers.
Not a fit: Patients without a confirmed PH diagnosis, adults, or those unable to provide consent or commit to follow-up are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the registry could improve understanding of pediatric PH progression and help refine risk scores and treatment approaches tailored to children.
How similar studies have performed: Other pediatric PH registries (for example TOPP and elements of REVEAL) have produced valuable natural-history and risk-stratification data, but pediatric therapeutic evidence remains limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Children and adolescents aged \<18 years at diagnosis * Diagnosed pulmonary hypertension (PH) according to the prevailing diagnostic criteria at the time of enrollment * Enrollment in the registry at participating centers * Provision of informed consent by patients and/or legal guardians * Availability for longitudinal follow-up Exclusion Criteria: * Inability to confirm PH diagnosis due to insufficient clinical or hemodynamic data * Refusal or inability to provide informed consent
Where this trial is running
Guangzhou, Guangdong
- Guangdong Provincial People's Hospital — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: Jie-Xin Zhang, Dr.
- Email: jx_zhang_vip@163.com
- Phone: +86-18629534652
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.